Since 1985, Cancer Progress is the only oncology conference that invites a discussion of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives in two days of interactive dialogue. Pivotal topics, frank discussions, vigorous debate, lively audience participation and generous networking throughout the meeting during breaks, luncheons, reception and dinner combine to make this a highly impactful conference.
Our 28th Annual Meeting on March 7-8, 2017 will provide an unsurpassed learning experience for participants in quality of information, coverage of issues, and value of professional contacts. The quality of the speaking faculty is a major contributor to the popularity and value of this conference.
We look forward to seeing you at the 28th Annual Cancer Progress Conference on March 7-8, 2017 at the Westin New York at Times Square!
THANK YOU TO OUR PRIOR YEAR SPONSORS
Cancer Progress 2017 Registration Rate
Regular Rate as of December 16 (Pharma, Biotech, Device, Dx): $2150
Industry Additional registrant from the same company: $1900
Industry one day rate: $1350
Service Provider: $2500
Service Provider one day rate: $1500
The registration fee covers your attendance at the meeting, handbook, continental breakfasts,
luncheons and reception.
Registration Cancellation Policy:
Registrants may cancel up to February 1 for a full refund less a $200 processing charge.
Cancellations after 30 days prior to the conference: Please send someone in your stead, or we will apply a
credit to Cancer Progress 2018 on your behalf.
Please submit conference refund requests to Ginny Llobell at email@example.com
or call 973.292.5001 Extensions 252 or 235 for assistance.
“I truly enjoyed the conference. I told several colleagues and friends that this has been one of the best conferences I have ever attended.”
Christoph Lengauer, Chief Scientific OfficerBlueprint Medicines
“What an unbelievable 2-day event that was. The intimate atmosphere (I made great new contacts) and dynamic (sometimes “dynamic tension”) interaction between panel members was fantastic. I kept great notes and have already shared the very enthusiastic feedback & takeaways with my management team.”
Armand Girard, Vice President, Corporate DevelopmentGlycomimetics
“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”
Noemi RosaNovartis Inc.
“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”